Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA4
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Advanced Research Projects Agency (DARPA) has issued a Special Notice under its "Biological Technologies" Broad Agency Announcement (BAA) HR001126S0003 for the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program - Task Area 4 (TA-4). This notice seeks support for the commercialization and manufacturing of technologies developed under RAPIID, aiming to create a shelf-stable blood analog system. Abstracts are due June 29, 2026, by 3:00 PM Eastern Time.
Purpose & Scope
DARPA's RAPIID program aims to develop a shelf-stable, blood analog system that can be manufactured at scale and rapidly advance toward regulatory authorization (e.g., EUA or FDA Approval) within three years. This Special Notice specifically targets Task Area 4 (TA-4), focusing on commercialization and sustainment. The objective is to engage the community, address program needs, and outline the timetable for full proposal submission for TA-4.
Key Requirements
The selected TA-4 performer will be responsible for developing an overarching, modular, and adaptable commercialization, manufacturing, and transition framework. This framework must integrate components for:
- Financing and investor engagement.
- Scalability and manufacturing capacity.
- Market entry, addressing regulatory, competitive, reimbursement, and adoption challenges.
- Licensing and transition strategies. Additionally, the TA-4 performer will conduct market research, support TA-1 and TA-2 performers with pitch and manufacturing strategies, and provide DARPA with assessments on supply chain resilience, market access, pricing, and manufacturing strategies.
Contract Details
- Type: Other Transaction Agreement (OTA).
- Program Structure: Designed for two phases over 36 months; this solicitation is for Phase 1 (months 1-12) only.
- Set-Aside: None specified.
- Product Service Code: AC12 (National Defense R&D Services; Department Of Defense Military; Applied Research).
Submission & Evaluation
- Abstract Due Date: June 29, 2026, by 3:00 PM Eastern Time.
- Full Proposal Package: Due approximately 3 weeks after invitation.
- Proposers must submit an abstract and receive an invitation before submitting a full proposal.
- Abstracts must address only TA-4. Proposers for TA-4 cannot propose for TA-1 or TA-2 to avoid Organizational Conflicts of Interest (OCI).
- Evaluation Criteria: Overall Scientific and Technical Merit, Proposer's Capabilities or Related Experience, Potential Contribution and Relevance to the DARPA Mission, and Cost and Schedule Realism.
- All communications and proposals must be submitted through the Broad Agency Announcement Tool (BAAT). Teaming is encouraged.
Contact Information
- Primary Contact: LCDR Robert Murray, Program Manager, DARPA/BTO
- Email: RAPIID@darpa.mil